On July 30, Sanofi SA declined 6.38% in regular trading, trading at $42.02/share, with turnover of $115 million.

On the news front, Sanofi reported Q2 earnings before market open, with the new CEO making a first public appearance and raising full-year guidance. Despite the upbeat outlook, market reaction turned negative as investors focused on the company's deepening pipeline concerns. The stock had already fallen approximately 3% in pre-market trading before losses accelerated during regular hours.

The sell-off reflects growing strategic anxiety over Sanofi's drug development pipeline. Core product Dupixent's patent is set to expire early next decade, and the company has yet to present a clear replacement capable of filling the resulting revenue gap. Recent setbacks have compounded fears: on July 24, Sanofi halted amlitelimab development for atopic dermatitis, while in June it terminated a phase 3 trial of riliprubart. Over the past 12 months, a series of negative clinical trial results has driven shares down roughly 13%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)